挪威髋部骨折登记2008至2020年显示:股骨转子间AO/OTA A1和A2骨折采用滑动髋螺钉或髓内钉手术后的死亡率相当
基于挪威髋部骨折登记2008年1月至2020年12月26,393例股骨转子间AO/OTA A1和A2骨折患者(髓内钉9,095例,滑动髋螺钉17,298例),比较两种内固定后的死亡率。调整后30天死亡率无显著差异(HRR 0.94,95%CI 0.86至1.02,p=0.146);髓内钉在0至1天死亡率较高(HRR 1.63,95%CI 1.13至2.34,p=0.009),8至30天死亡率略低(HRR 0.89,95%CI 0.80至1.00,p=0.043)。作者认为观察到的死亡率差异很小,可能不应据此选择治疗方式。
要点
- 调整后髓内钉与滑动髋螺钉的30天死亡率无显著差异(HRR 0.94,95%CI 0.86至1.02,p=0.146)。
- 髓内钉0至1天死亡率高于滑动髋螺钉(HRR 1.63,95%CI 1.13至2.34,p=0.009),需伤害人数为556。
- 髓内钉8至30天死亡率略低于滑动髋螺钉(HRR 0.89,95%CI 0.80至1.00,p=0.043)。
核心结论
- 本研究未发现髓内钉与滑动髋螺钉在30天死亡率上有差异。
- 髓内钉与0至1天死亡率较高相关,并与8至30天死亡率略低相关。
- 观察到的死亡率差异很小,可能不应据此指导治疗选择。
研究设计与样本
- 分析挪威髋部骨折登记2008年1月至2020年12月数据,纳入26,393例股骨转子间AO/OTA A1和A2骨折患者,其中髓内钉9,095例、滑动髋螺钉17,298例。
- 排除年龄小于60岁、病理性骨折、2008年前手术、对侧髋部骨折、非转子间A1/A2骨折以及非髓内钉或滑动髋螺钉治疗的患者。
- 采用Kaplan-Meier分析和Cox回归分析,调整骨折类型、年龄、性别、认知障碍、美国麻醉医师协会(ASA)分级和时间段,并计算需伤害人数(NNH)。
主要发现
- 未调整分析中,髓内钉与滑动髋螺钉30天生存率无显著差异(91.8% vs 91.1%,p=0.083),90天生存率无显著差异(85.4% vs 84.5%,p=0.065),但髓内钉一年生存率高于滑动髋螺钉(74.5% vs 73.3%,p=0.031)。
- 调整后30天死亡率无显著差异(HRR 0.94,95%CI 0.86至1.02,p=0.146)。
- 髓内钉0至1天死亡率高于滑动髋螺钉(HRR 1.63,95%CI 1.13至2.34,p=0.009),需伤害人数为556。
- 髓内钉8至30天死亡率低于滑动髋螺钉(HRR 0.89,95%CI 0.80至1.00,p=0.043)。
- 2至7天(HRR 0.94,95%CI 0.79至1.11,p=0.434)、90天(HRR 0.95,95%CI 0.89至1.02,p=0.177)和365天(HRR 0.97,95%CI 0.92至1.02,p=0.192)死亡率无差异。
关键数值与推荐
- 主要终点为30天死亡率,次要终点为0至1天、2至7天、8至30天、90天和365天死亡率。
- 调整后30天死亡率HRR 0.94(95%CI 0.86至1.02),p=0.146。
- 0至1天死亡率HRR 1.63(95%CI 1.13至2.34),p=0.009,需伤害人数556。
- 8至30天死亡率HRR 0.89(95%CI 0.80至1.00),p=0.043。
临床怎么用
- 作者认为观察到的死亡率差异很小,可能不应据此指导治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study aimed to compare mortality in trochanteric AO/OTA A1 and A2 fractures treated with an intramedullary nail (IMN) or sliding hip screw (SHS). The primary endpoint was 30-day mortality, with secondary endpoints at 0 to 1, 2 to 7, 8 to 30, 90, and 365 days. METHODS: We analyzed data from 26,393 patients with trochanteric AO/OTA A1 and A2 fractures treated with IMNs (n = 9,095) or SHSs (n = 17,298) in the Norwegian Hip Fracture Register (January 2008 to December 2020). Exclusions were made for patients aged < 60 years, pathological fractures, pre-2008 operations, contralateral hip fractures, fractures other than trochanteric A1/A2, and treatments other than IMNs or SHSs. Kaplan-Meier and Cox regression analyses adjusted for type of fracture, age, sex, cognitive impairment, American Society of Anesthesiologists (ASA) grade, and time period were conducted, along with calculations for number needed to harm (NNH). RESULTS: In unadjusted analyses, there was no significant difference between IMN and SHS patient survival at 30 days (91.8% vs 91.1%; p = 0.083) or 90 days (85.4% vs 84.5%; p = 0.065), but higher one-year survival for IMNs (74.5% vs 73.3%; p = 0.031) compared with SHSs. After adjustments, no significant difference in 30-day mortality was found (hazard rate ratio (HRR) 0.94 (95% confidence interval (CI) 0.86 to 1.02(; p = 0.146). IMNs exhibited higher mortality at 0 to 1 days (HRR 1.63 (95% CI 1.13 to 2.34); p = 0.009) compared with SHSs, with a NNH of 556, but lower mortality at 8 to 30 days (HRR 0.89 (95% CI 0.80 to 1.00); p = 0.043). No differences were observed in mortality at 2 to 7 days (HRR 0.94 (95% CI 0.79 to 1.11); p = 0.434), 90 days (HRR 0.95 (95% CI 0.89 to 1.02); p = 0.177), or 365 days (HRR 0.97 (95% CI 0.92 to 1.02); p = 0.192). CONCLUSION: This study found no difference in 30-day mortality between IMNs and SHSs. However, IMNs were associated with a higher mortality at 0 to 1 days and a marginally lower mortality at 8 to 30 days compared with SHSs. The observed differences in mortality were small and should probably not guide choice of treatment.
引用
- Ahmad A, Egeland EH, Dybvik EH, et al. Equivalent mortality after operation with sliding hip screw or intramedullary nail for trochanteric AO/OTA A1 and A2 fractures reported in the Norwegian Hip Fracture Register 2008 to 2020. Bone Joint J. 2024. PMID: 38821494. doi:10.1302/0301-620X.106B6.BJJ-2023-1219.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。